Compare Repligen Corporation Common Stock (RGEN) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs ProShares Ultra Gold ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while ProShares Ultra Gold ETF trades at $45.22 (market cap $730.54M). The key difference: Repligen Corporation Common Stock is far larger — about 15.2× ProShares Ultra Gold ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| RGEN | UGL | |
|---|---|---|
Market Cap | $11.14B | $730.54M |
Volume | 1,259,263 | 1,700,224 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $85.62 |
52-Week Low | $102.87 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
UGL is trading at $45.70, down 0.39% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights gold price volatility amid shifting Fed rate expectations and Treasury yield pressures, influencing sentiment.
The outlook remains cautious due to technical weakness and macroeconomic headwinds. Risks include persistent rate-hike uncertainty and gold market sensitivity. Investment potential hinges on future financial disclosures and gold price stabilization, but current data gaps and bearish signals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
